NBIX vs PTCT

For growth investors, PTC Therapeutics, Inc.

(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus 21. 4% for Neurocrine Biosciences, Inc. (NBIX). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 8. 3x trailing P/E, making it the more compelling value choice. Analysts rate Neurocrine Biosciences, Inc. (NBIX) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, PTC Therapeutics, Inc.

(PTCT) is the cheapest at 8. 3x versus Neurocrine Biosciences, Inc. at 32. 0x.

Over the past 5 years, Neurocrine Biosciences, Inc.

(NBIX) delivered a total return of +64. 3%, compared to +60. 3% for PTC Therapeutics, Inc. (PTCT). Over 10 years, the gap is even starker: PTCT returned +733. 2% versus NBIX's +233. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Neurocrine Biosciences, Inc.

(NBIX) is the lower-risk stock at 0. 76β versus PTC Therapeutics, Inc. 's 1. 13β — meaning PTCT is approximately 50% more volatile than NBIX relative to the S&P 500.

By revenue growth (latest reported year), PTC Therapeutics, Inc.

(PTCT) is pulling ahead at 114. 5% versus 21. 4% for Neurocrine Biosciences, Inc. (NBIX). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to 41. 9% for Neurocrine Biosciences, Inc.. Over a 3-year CAGR, PTCT leads at 35. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PTC Therapeutics, Inc.

(PTCT) is the more profitable company, earning 39. 4% net margin versus 16. 7% for Neurocrine Biosciences, Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus 21. 6% for NBIX. At the gross margin level — before operating expenses — NBIX leads at 98. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PTCT: 39.

0% to $89. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Neurocrine Biosciences, Inc.

(NBIX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 76), +233. 2% 10Y return). Both have compounded well over 10 years (NBIX: +233. 2%, PTCT: +733. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.